Soligenix (OTCBB: SNGXD) announced results from its phase 1/2 clinical trial of SGX201 for the prevention of acute radiation enteritis. The press release covers how the study demonstrated that oral administration of SGX201 (beclomethasone) was safe and well tolerated across all four dose groups.
There was also evidence of a potential dose response with respect to diarrhea, nausea, and vomiting and the assessment of enteritis according to NCI Common Terminology Criteria for Adverse Events for selected gastrointestinal events. In addition, the incidence of diarrhea was lower than that seen in recent published historical control data in this patient population.